chrisvoncsefalvay/vaers-outcomes huggingface dataset:
received vaccine 6/22/2021. Admitted to the Hospital 12/31/2021 for evaluation of stroke.  Found to have elevated blood pressure and no stroke.  Never developed symptoms of COVID. Discharged 1/3/2022 to home from hospital.
Pt felt lightheaded and dizzy. She was anxious and felt warm. Small amount of tremor.
I received the COVID-19 Vaccine EUA booster shot and suffered 24 hours of atrial fibrillation with chest pain and light headedness starting two nights after the injection. On the first three days I felt fever and chills with muscle ache and soreness at the injection site which I felt was normal. The A-fib was intense. I was able to control it with Diltiazem 30 mg, (4 doses over 18 hours).
Extreme fatigue. I felt like I had been hit by a truck. Slept all day.
Initial and follow-up information has been received from a nurse practitioner concerning her daughter a 14 year old female with scoliosis and no previous pregnancies who in 2007 was vaccinated with the first dose of GARDASIL 0.5ml IM when she was 17 weeks pregnant. On 25-JUL-2007 the patient was vaccinated with the second dose of GARDASIL (lot # 656050/0245U). Concomitant vaccine on 25-JUL-2007 included DTAP (unspecified) and meningococcal vaccine (unspecified). The male baby was born healthy on 04-JAN-2008. There were no congenital anomalies or other complications. The baby weighed 7 pounds, 3.8 ounces and was 21 inches long. APGAR scores were 9/9 the patient sought medical attention. Additional information is not expected. In follow up medical records were received. It was reported that the patient had had induced vaginal delivery with no complications, mild decelerations during delivery. Subsequently, the baby developed rash after receiving ROTATEQ (WAES #0903USA03600). Upon internal review of the file, it was found the baby was born with birthmark back of head. Upon internal review, birthmark back of head was determined to be a congenital anomaly. Follow up information was received from the NUrse Practitionar (N.P) who reported that the birthmark on the patient was a non elevated, beige pigmented area (slightly darker than his skin tone) on the child's left lower leg (previously reported as on the back of the head) measuring a little over 1/2 inch long and 1/4 inch wide. It was reported that the N.P was the child's grandmother and further reported that was seemed to be a family trait as she had a similar birthmark as did her daughter (the child's mother). It was reported that the physician wanted clarification about the baby's birthmark. All medical records are available upon request. This is in follow-up to report (s) previously submitted on 4/14/2009.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. In or around January 2016, the patient was inoculated with the ZOSTAVAX (lot number, dosage and route of administration not provided) for routine health maintenance and for its intended purpose: the prevention of shingles. In approximately 2016 [reported as shortly after receiving ZOSTAVAX], the patient suffered from shingles. As a direct and proximate result of ZOSTAVAX, the patient's symptoms have resulted in physical limitations not present prior to using ZOSTAVAX. The patient also experienced mental and emotional distress due to resulting physical limitations and the seriousness of her condition. As a result of the ZOSTAVAX, the patient sustained severe and permanent personal injuries. Further, as a tragic consequence, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate consequence of ZOSTAVAX, the patient sustained serious personal injuries and related losses including, but not limited to, the following: The patient required and will continue to require healthcare services; the patient incurred and will continue to incur medical and related expenses; and the patient suffered and will continue to suffer mental anguish, physical pain and suffering, diminished capacity for the enjoyment of life, a diminished quality of life, and other losses and damages. The outcome of the shingles was considered to be not recovered. Shingles was considered to be disabling. Additional information has been requested.
Since the initial injection given i have had a knot in my arm. the soreness is gone and i did not have any other symptoms after the injection. I still have the knot in my arm, it is itchy, some burning sensation, raised, red,  and hot to the touch. again no other symptoms such as fever, muscle aches, and or fatigue.
. headache; arm swelling; arm soreness; This is a spontaneous report from a non-contactable consumer, the patient. A 49-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 26May2021 at 14:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 05May2021 at 14:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation.  The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27May2021 at 10:00, the patient experienced headache, arm swelling and soreness. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events of  headache, arm swelling and soreness was not recovered at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained
Short Term Memory Loss, Painful Aches - Joints of whole body, Fatigue and now as of Dec 14,2010 - sexual impotence.
Same symptoms returned last night; Chills; Aches and pains; Headache; Tired; This spontaneous case was reported by a patient and describes the occurrence of SYMPTOM RECURRENCE (Same symptoms returned last night), CHILLS (Chills), MYALGIA (Aches and pains), HEADACHE (Headache) and FATIGUE (Tired) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001B21A and 001A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Mar-2021, the patient experienced CHILLS (Chills), MYALGIA (Aches and pains), HEADACHE (Headache) and FATIGUE (Tired). On 30-May-2021, the patient experienced SYMPTOM RECURRENCE (Same symptoms returned last night). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 26-Mar-2021, CHILLS (Chills), MYALGIA (Aches and pains), HEADACHE (Headache) and FATIGUE (Tired) had resolved. On 30-May-2021, SYMPTOM RECURRENCE (Same symptoms returned last night) had resolved.            No relevant concomitant medications were reported. Action taken with mRNA-1273 in response to the events was not applicable. The same symptoms (chills, aches and pains, headache, and tiredness) recurred on 30 May 2021.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Apr-2021 at 10:57 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 03-Apr-2021 at 10:57 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 60.82 for dose administered on 03-Apr-2021.  No concomitant medications were reported.  Batch number 030B21A administered on 03-Apr-2021 underwent temperature excursion with temperature of 34 degrees Fahrenheit at 09:00 AM. This vial was moved to fridge on 30-Mar-2021 and beyond use date for the vial was reported as 29-Apr-2021. Product moved to clinic on 03-Apr-2021.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a traceable temperature monitor at every hour.  The vial was not in a frozen state at the time of vaccine administration. It was reported that, the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021. The health care professional explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34- or 35-degree Fahrenheit. Treatment medications were not reported.  No treatment medications were reported.
I got tired; She felt headache on right side of her head/getting migraines but only on the right side of my head; This is a spontaneous report from a contactable female consumer (patient) reported for herself via Pfizer Sponsored Program. A female patient of unspecified age received first dose of BNT162B2 (Pfizer covid-19 vaccine, Solution for Injection, Lot number: Unknown, Expiration date: Unknown), via an unspecified route on 22May2021, as a single dose for covid-19 immunization. Medical history included anaphylactic reaction which patient got before in her life. The patient concomitant medications were not reported. On an unknown date after first dose, patient got tired and started getting migraines but only on the right side of the head. The clinical outcome of the migraine was gone away and fatigue was unknown. Information about lot/batch number has been requested.
Day after receiving final Hep B inj his rt arm became painful with movement and has persisted for 2 wks. and deep joint pain with movement.
Pt. reports redness & swelling approximately 4 cm in diameter. Red area was warm to touch. Pt. also reports itching.
Patient received the Covid-19 vaccine. She reports symptoms of itchiness, swelling, and dizziness.  Pt stayed in the clinic for an additional 30 min after Diphenhydramine 50 mg/mL (1002) was given IM in right deltoid.   Vitals:  1002:  B/P: 102/60 HR: 102/60 O2: 96 RR: 16  1015: B/P: 98/62 HR: 82 O2: 99 RR: 12   1023 B/P: 100/62 HR: 76 O2: 99 RR: 18
Encounter Background Information: Referred by doctor on 3/1/07 with large local reaction to arm following influenza vaccine. Received IM influenza on 2/27/07 (has had several times before w/o AE). Within 4-8 hours post immun her arm developed a red rash at the site, swollen, tender, afebrile w/o "bumps" just redness at site later 6x5inches circular diameter. It did not encircle the arm. Site was pruritic. Also had headache, fatigue and overall body aches which have resolved/eased 24 hours later. Concerned if this was a normal reaction or an adverse event to be concerned with. She wore a bandaid over site all day, possible latex components. Reported history of Latex allergies (skin rash, peeling skin requiring prednisone use), several drug and environmental allergies. She reported allergy to epi (hypertensive crisis and tremors) and steroid creams (peeling skin/rash). Allergy to alcohol. Hx asthma, HTN, GERD, migraines, and bowel disorders. On numerous medications. She contacted office who stated she believed this was a latex reaction but referred for f/u. Skin symptoms swelling, redness to vaccine site 6 hours after vaccinated with red rash. Swelling reported to be 6 in x 4.5 in extending 1/2 way to elbow. was itching w/o bumps. Arm tender. Wearing latex bandaid over vac site until late that night and removed. No otolaryngeal symptoms, No cardiovascular symptoms, No pulmonary symptoms.
Pt indicated that 5 employees have not converted; some employees recvd 2 courses of Engerix-B;
Pt. reported painful lump (L) deltoid within a few hours of receiving Tdap. 3 days later on 7/28/12 noticed tender swelling (L) axilla. Lump was the size of a nickel. On 7/31/12 developed soreness across upper chest and unable to relate to any other cause. Painful to sit up down with movement of torso/arms. Some relief with ibuprofen. As of 8.1.12 only mild tenderness of deltoid and axilla. Advised to see PCP for the chest pain but declined- will wait to see if it resolves.
Swollen arm, Redness at injection site Heart palpitations Fatigue Muscle soreness Loss of appetite Headache Chills
6 cm erythema left deltoid. Triamcinolone topical 0.1% TID to left deltoid area.
Patient falsified DOB when registering for vaccination. Guardian, consented to the vaccination. Department of Health verified with statistical records patients actual DOB, which made the vaccine a contraindication.  No known adverse reactions noted.
Patient started having slight chills, muffled sound in ear, and sweating about 5 minutes after 2nd dose of the Pfizer vaccine was given.  I gave patient water and asked if he wanted me to call EMS to which he agreed as a precaution.  By the time EMS arrived, patient stated that it all "had passed" and he felt fine to go home.  He then stated that he had a similar reaction previously to a flu shot.
Injection site pain; redness; This case was reported by a consumer and described the occurrence of neck pain in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On 6th December 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 3 months after receiving Shingrix, the patient experienced neck pain, shoulder pain, injection site pain and injection site erythema. On an unknown date, the outcome of the neck pain, shoulder pain, injection site pain and injection site erythema were unknown.   It was unknown if the reporter considered the neck pain, shoulder pain, injection site pain and injection site erythema to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group of the patient selected as an adult as per vaccine indication. Th patient stated that, had sever injection site pain and redness after vaccination. The patient did not experienced headache and muscle pain after 1st Shingrix vaccination. For tollerence of 2nd dose refer case US2020AMR033936, reported by same reporter for the same patient.
This case reference number 2000005000-1 is a spontaneous report from a physician. Allergies, medical history, and concomitant medications are not specified. On approximately 11/16/99, the patient received her third dose of Engerix-B. On 01/11/00, eight weeks later, the patient was found to have elevated liver function tests. (Please see laboratory section for details.) One month later, on 02/11/00, her laboratory levels were normal. The patient was advised that this was a possible transient adverse reaction. The most recent information, received on 02/14/00, reports the condition of the patient is resolved.
Weak, numb heavy right arm, Weak left arm, Weak numb  right leg and paralysis of the left leg.  Sensory loss and numbness from nipple line down.   Neurogenic bladder and muscle spams in left and right legs.   Movement has improved and strength in right arm and right leg   Left leg still weak and neurogenic bladder still an issue.    No sensory improvement yet.
Hospitalized;  COVID-19 positive 8.27.21;  fully vaccinated (still hospitalized currently) Patient is a 56 y.o. female  who presents to hospital. Patient only speaks Spanish, translator was used during the interview. The patient states that she has been having difficulty breathing, back pain, and worsening cough and worsening fatigue. It all started On Saturday she developed a headache and a fever. Monday, everything got progressively worse. Came in today mainly because of the worsening shortness of breath. She had a Johnson and Johnson vaccination back in April. Chief complaint; SOB, weakness. Problem List; Principal Problem: COVID-19; Active Problems: Elevated LFTs, Hypoxia; Assessment and Plan: Medical Decision Making; Sepsis secondary to COVID 19, No respiratory distress, only requiring 2L/min oxygen. Start on Decadron and Remdesivir. Date of symptom onset: 8/21/2021.
Pt recvd vax on 20JUL92 & lab eval revealed elevated liver enzymes, & elevated ANA; repeat lab eval revealed elevated liver enzymes; No further details were provided;
swelling at injection site; pain; itching; experienced itching and crinkles; This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   In September 2020, the patient received Shingrix. In September 2020, less than a week after receiving Shingrix, the patient experienced injection site swelling, pain and pruritus. On an unknown date, the patient experienced wrinkles. On an unknown date, the outcome of the injection site swelling, pain, pruritus and wrinkles were unknown.   It was unknown if the reporter considered the injection site swelling, pain, pruritus and wrinkles to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix, a week ago from the date of reporting. After receiving Shingrix, the patient experienced swelling at injection site and tolerable pain but a week later, the patient experienced itching and crinkles.  The reporter did not consent to follow-up.
Temperature 104°F x 36 hrs beginning on 4/27, severe fatigue x 7 days, mild fatigue after that until current time, swelling of 12cm/redness/pain/hot to touch at injection site starting on 4/30/21 and ending 5/2/21.
Swollen, red, and warm. Itching at temperature site. Itching after injection with large red, warm area size of orange at injection site withitching.
First two days very sore arm, similar to tetanus shot.  Yesterday and today (days 3-4) I have had slight nausea, mild diarrhea and decrease appetite.  A little more tired also.
This spontaneous report was received from a consumer, via Pfizer (Mfr. Control N 2016076426) referring to a female patient of unknown age with chronic obstructive pulmonary disease (COPD), she never smoked but she also had emphysema and bronchitis. In February 2015, the patient was vaccinated with a dose of PNEUMOVAX 23 (Lot#, expiration date, dose and route of administration were not reported). Concomitant medication was not reported. On 22-DEC-2015, the patient experienced pneumonia. The outcome and causality of pneumonia was unknown. Additional information has been requested.
Sore arm-4 days, chills-2 days, facial numbness on left side of mouth, tongue, lips, upper and lower. Tongue on left was sore. Could not feel lips on left only. Numbness lasted approximately 5-6 days. Pain on left lower gum line and upper gums.
Initially post vaccination, patient had redness, swelling  and heat at the vaccination site, in addition to head ache.  This resolved.  On day 9 patient noted, site was itchy, quarter size "bump", and redness.  Continues to experience headaches.  As of 1/7, redness and swelling are gone, continues with headaches and reports intermittent sharp pain to anterior deltoid region.  Upon inspection of the area, no redness but small area of selling noted, lower deltoid.
Severe malaise starting less than 1 hour after receiving vaccine. Possible syncope and altered mental status starting about 2 hours after receiving vaccine and lasting about 45 minutes.  10/06/09 Received hospital medical records for 9/24-9/26-2009. FINAL DX: allergy to flu shot vaccine; syncope w/LOC & altered mental status due to allergic reaction; pancytopenia c/w cirrhosis & interferon tx. Records reveal patient experienced malaise s/p flu vaccination, fell & was unresponsive at home w/lengthy recovery time.  Then developed achiness, HA, eye swelling, orthostatic BP.  Tx w/IVF, steroids.  Progressed well & d/c to home. ICD9 codes: 78009; 7802; 2841; 78009; E9496; 37992; 7242
06/04/2022 I woke up with a bloody nose and my blood pressure was up. It took half an hour before my bloody nose slowed down and another 10 minutes before it stopped. My blood pressure was 157/90 around 10:00 that morning. My throat felt raw and was sore for about 3 days. My blood pressure went back to a normal range about 3 days later. I feel fine now.
Initial report received from a health care professional on 24 May 2011. A 33-year-old female patient with a medical history of shingles received a left deltoid intramuscular injection of ADACEL, sanofi pasteur Inc. lot number U3958AA and sanofi pasteur Ltd. lot number C3983, on 09 May 2011. The patient had a medical history of shingles. She had no illness at the time of vaccination. Her concomitant medications were unknown. The patient's last TD was in 1999. On 10 May 2011, per the patient's private physician, she broke out with shingles 24 hours post vaccination. The patient has had previous breakouts and breakouts while pregnant. The outcome was reported as unknown. Documents held by sender: None.
This spontaneous report as received from a medical assistant refers to a 4 month old patient of unknown gender. The patient's concurrent conditions, medical history, concomitant medications, drug reactions and allergies were not reported. On 02-OCT-2018, the patient was vaccinated with improperly stored dose of ROTATEQ 2 ml tube, orally (lot # N022015, expiry date: 10-MAR-2019) for prophylaxis. The vaccine was exposed to the temperature of 32.21 degree Fahrenheit (°F) (32F to 35 F) and time frame was 3.5 hours from 06-SEP-2018. Previous excursion was 50.37°F for 4.5 hours as recorded by a data logger. No adverse effect was reported. No product quality complaint was involved. This is one of the several reports received from the same reporter source. Sender's Comments: US-009507513-1809USA002868: Original Case: 1809USA002868; US-009507513-1902USA009324: Original Case: 1902USA009323; US-009507513-1902USA009323: Original Case: 1902USA009323; US-009507513-1902USA009326: Original Case: 1902USA009323.